Dr Pagani talks to ecancertv at ASCO 2014 about the results of a landmark study that was a joint analysis of two phase III trials, TEXT and SOFT, which demonstrated that the aromatase inhibitor exemestane more effectively prevents breast cancer recurrences than tamoxifen when given with ovarian function suppression in premenopausal women with hormone-sensitive cancers.
Read the article or watch the press conference for more.
ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.